DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious ischemic diseases, including acute ischemic stroke and preeclampsia. The company's lead candidate, DM199, is a recombinant form of the KLK1 protein being studied for its therapeutic potential in vascular diseases.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.